With a legal market size last year of around $2.7 billion,
which is projected to expand by a whopping 300 percent over the next four years
to around $10.8 billion according to a recent report from ArcView Market
Research, the market for cannabis in the U.S. is fueling one of the fastest
growing industries the country has to offer. Given that there is yet
considerable room for expansion nationwide, as well as positive/widespread
consumer sentiment that continues to drive legislative easing of legal restrictions
on both medical and recreational use, the industry is primed to blossom
nationally, from medical marijuana (MMJ) being legal in just 23 states, D.C.
and the territory of Puerto Rico, and recreational use being allowed in Alaska,
Colorado, D.C., Oregon and Washington.
The profound benefits of easily tolerable and safe medicines
based on established and emerging cannabis science, which have been
demonstrated thus far in areas like epilepsy, largely speak for themselves and
this vector is an extremely important one for the future of the industry as
well, as it will continue to be the narrow end of the wedge for the development
of the broader market. This market will eventually contain a rich variety of
everything from edibles and extracts by developers like Nutritional High
International (OTCQB: SPLIF), to frontline cannabinoid medicines from companies
like GW Pharmaceuticals (NASDAQ: GWPH), such as the multiple sclerosis-related
spasticity drug Sativex®, or the recently FDA Orphan Drug Designation approved
Epidiolex©, designed to treat severe forms of epilepsy.
Another major driver of legislative reform on this issue has
of course been tax revenue and with Washington recently noting how it has
successfully emulated Colorado’s own achievements in this area, raking in some
$250 million in sales over the past year and realizing around $62 million in
excise taxes (a figure 72 percent higher than initially forecast), it doesn’t
take a rocket scientist to figure out what the future of the cannabis industry
here in America will look like. Indeed, it feels like the end of the alcohol
prohibition era to many investors and some of the small to mid-cap companies
out there today, who are still just cutting their teeth, could be tomorrow’s
juggernauts, rivaling some of the top players in the $170 billion plus U.S.
alcoholic beverages market, like Anheuser-Busch InBev (NYSE: BUD), Diageo
(NYSE: DEO), and Molson Coors (NYSE: TAP).
The key to maturing into such a juggernaut however is a
difficult to pull off combination of visionary business modeling, talented
personnel, logistical capacity, marketing, understanding of the end-user
dynamics, and most importantly the quality of the product itself. This is where
an up-and-coming biopharma development company with strong roots in
cutting-edge plant biology and cultivation technology like GrowBLOX Sciences
(OTC: GBLX) really shines. With an integrated approach to the market, spanning
its proprietary grow technology based on tissue sample-based cloning and a
controlled environment that yields consistently high-grade product, which is
ideal for both consumers and pharma development purposes alike, through to a
well-thought-out commercialization and marketing strategy, GBLX is one of the
few “pot stocks” around today with a full-spectrum approach to the industry
that could emerge as a one of tomorrow’s sector juggernauts.
By leveraging the company’s proprietary TissueBLOX,
GrowBLOX, and CureBLOX platforms, GBLX is able to deliver genetically
consistent, high-grade strains of certified raw cannabis materials and blends
that will not only resonate with consumers in the end markets and fetch premium
prices, while simultaneously priming the pump for accelerated human trialing of
cannabis-based medicines. Because the company’s lab-based analytical methods
allow GBLX to make precise determinations about key strains and the profile of
active ingredients in those strains, and because of the company’s tight
post-processing via its ExtractionLAB technology, GrowBLOX Sciences is
effectively at the forefront of cannabis drug discovery capabilities, due to
its ability to target and cultivate the best strains, and to do so in an
environment which eliminates almost all of the variables that otherwise
represent risk factors that must be compensated for.
Able to reduce the typical 15 to 20 year development window
and billion plus required to bring a new drug to market, GBLX’s accelerated
drug discovery program harnesses in-house strain science, the ability to
cultivate genetically pure and identical plants, as well as the processing
technology needed to rapidly establish FDA FastTrack Approvals or Orphan Drug
designations. Moreover, the company’s GBLX-PRO app leverages Big Data
harvesting techniques in order to create a real-time feedback loop with end-users,
allowing for the rapid establishment of highly coordinated strain profile
information, cannabis safety profiling, and usage-based symptom relief data.
Cannabis-based medicine development targets run the gamut from cancer
treatments, cardio protection, compromised immune system products and
inflammation fighters, to indications for treating metabolic syndrome,
neurological disorders like epilepsy, and more standard fare such as pain
management.
The combination of this accelerated drug discovery pipelining
solution with the revenue potential from consistently high-grade materials and
blends output to the dispensary market is only the beginning of the story for
GBLX though, as the company has already shipped out production-model GrowBLOX
units to its GB Sciences Nevada and GB Sciences Puerto Rico operations. With a
$1.75 million funding commitment established via Pacific Leaf Ventures to get
the company’s 4000 pounds per year Nevada-based Cultivation Lab up and running,
as well as a clean, highly-efficient brick and mortar dispensary model known as
The Apothecary in the works, and an advanced vending machine on the table that
easily rivals or surpasses Medbox’s implementation (OTC: MDBX), GrowBLOX
Sciences is already well on its way to becoming one of the top integrated
operators in the industry.
Tight branding and marketing at the consumer level, combined
with high-grade product and an ability to consistently produced scalable
quantities for both direct consumption and drug development will be the keys to
GBLX’s long-term success.
Learn more by visiting www.growblox.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment